Balancing the innate immune system in tumor development

Trends in Cell Biology

Volumn 25, Issue 4, 2015, Pages 214-220

  Hagerling, Catharina ^a   Casbon, Amy Jo ^a   Werb, Zena ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer development; Inflammation; Innate immune cells

Indexed keywords

BONE MARROW CELL; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; DENDRITIC CELL; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; LYMPHOID CELL; NEUTROPHIL; NONHUMAN; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; REVIEW; T CELL SUPPRESSIVE MYELOID CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INITIATION; TUMOR MASSOCIATED NEUTROPHIL; CELL TRANSFORMATION; DISEASE COURSE; IMMUNOLOGY; NEOPLASM; TUMOR MICROENVIRONMENT;

CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HUMANS; IMMUNITY, INNATE; INFLAMMATION; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84922181550     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2014.11.001     Document Type: Review

References (100)

1. Mantovani A. Cancer: inflaming metastasis. Nature 2009, 457:36-37.
2. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
3. Mantovani A., et al. Cancer-related inflammation. Nature 2008, 454:436-444.
4. Elinav E., et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer 2013, 13:759-771.
5. Jemal A., et al. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
6. Bosch F.X., et al. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 2002, 55:244-265.
7. Grivennikov S.I., et al. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
8. Lakatos P.L., Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J. Gastroenterol. 2008, 14:3937-3947.
9. Elkahwaji J.E. The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer. Res. Rep. Urol. 2012, 5:1-10.
10. Coussens L.M., et al. Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 2013, 339:286-291.
11. Park E.J., et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140:197-208.
12. Takahashi H., et al. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell 2010, 17:89-97.
13. Gabrilovich D.I., et al. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268.
14. Modi B.G., et al. Langerhans cells facilitate epithelial DNA damage and squamous cell carcinoma. Science 2012, 335:104-108.
15. Noy R., Pollard J.W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014, 41:49-61.
16. Murray P.J., et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014, 41:14-20.
17. Lumeng C.N., et al. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 2007, 117:175-184.
18. Deng L., et al. A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. Am. J. Pathol. 2010, 176:952-967.
19. Balkwill F.R., Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin. Cancer Biol. 2012, 22:33-40.
20. Wynn T.A., et al. Macrophage biology in development, homeostasis and disease. Nature 2013, 496:445-455.
21. Jinushi M., et al. Regulation of cancer stem cell activities by tumor-associated macrophages. Am. J. Cancer Res. 2012, 2:529-539.
22. Kendellen M.F., et al. Canonical and non-canonical NF-kappaB signaling promotes breast cancer tumor-initiating cells. Oncogene 2014, 33:1297-1305.
23. Rajasekhar V.K., et al. Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-kappaB signalling. Nat. Commun. 2011, 2:162.
24. Bradford J.W., Baldwin A.S. IKK/nuclear factor-kappaB and oncogenesis: roles in tumor-initiating cells and in the tumor microenvironment. Adv. Cancer Res. 2014, 121:125-145.
25. Pattabiraman D.R., Weinberg R.A. Tackling the cancer stem cells - what challenges do they pose?. Nat. Rev. Drug Discov. 2014, 13:497-512.
26. Jinushi M., et al. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:12425-12430.
27. Yang J., et al. Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway. Stem Cells 2013, 31:248-258.
28. Marotta L.L., et al. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 2011, 121:2723-2735.
29. Grivennikov S., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
30. Lesina M., et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011, 19:456-469.
31. Mitchem J.B., et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013, 73:1128-1141.
32. Panni R.Z., et al. Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. Cancer Immunol. Immunother. 2014, 63:513-528.
33. Fukuda A., et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 2011, 19:441-455.
34. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat. Immunol. 2011, 12:715-723.
35. Liu K., et al. Sox2 cooperates with inflammation-mediated Stat3 activation in the malignant transformation of foregut basal progenitor cells. Cell Stem Cell 2013, 12:304-315.
36. Ho P.L., et al. Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Res. 2012, 72:3135-3142.
37. Myant K.B., et al. ROS production and NF-kappaB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. Cell Stem Cell 2013, 12:761-773.
38. Schwitalla S., et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 2013, 152:25-38.
39. Braumuller H., et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013, 494:361-365.
40. Iannello A., et al. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J. Exp. Med. 2013, 210:2057-2069.
41. Jung H., et al. RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry. J. Exp. Med. 2012, 209:2409-2422.
42. Marcus A., et al. Recognition of tumors by the innate immune system and natural killer cells. Adv. Immunol. 2014, 122:91-128.
43. Liu X.V., et al. Ras activation induces expression of Raet1 family NK receptor ligands. J. Immunol. 2012, 189:1826-1834.
44. Tokuyama M., et al. Expression of the RAE-1 family of stimulatory NK-cell ligands requires activation of the PI3K pathway during viral infection and transformation. PLoS Pathol. 2011, 7:e1002265.
45. O'Sullivan T., et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J. Exp. Med. 2012, 209:1869-1882.
46. Cai X., et al. Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155. J. Mol. Cell Biol. 2012, 4:341-343.
47. Shime H., et al. Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:2066-2071.
48. Pyonteck S.M., et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 2013, 19:1264-1272.
49. Movahedi K., et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010, 70:5728-5739.
50. De Palma M., et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8:211-226.
51. Altevogt P., et al. Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation. Semin. Cancer Biol. 2014, 28C:51-57.
52. Peinado H., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012, 18:883-891.
53. Yeo E.J., et al. Myeloid WNT7b mediates the angiogenic switch and metastasis in breast cancer. Cancer Res. 2014, 74:2962-2973.
54. Linde N., et al. Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages. J. Pathol. 2012, 227:17-28.
55. Mazzieri R., et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011, 19:512-526.
56. Forget M.A., et al. Macrophage colony-stimulating factor augments Tie2-expressing monocyte differentiation, angiogenic function, and recruitment in a mouse model of breast cancer. PLoS ONE 2014, 9:e98623.
57. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266.
58. Qian B.Z., et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475:222-225.
59. Ren G., et al. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFalpha. Cell Stem Cell 2012, 11:812-824.
60. Wolf M.J., et al. Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell 2012, 22:91-105.
61. Barcellos-Hoff M.H., et al. The evolution of the cancer niche during multistage carcinogenesis. Nat. Rev. Cancer 2013, 13:511-518.
62. Rohan T.E., et al. Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer. J. Natl. Cancer Inst. 2014, 106. 10.1093/jnci/dju136.
63. Shoenfeld Y., et al. Leukocytosis in non hematological malignancies - a possible tumor-associated marker. J. Cancer Res. Clin. Oncol. 1986, 111:54-58.
64. Tazzyman S., et al. Neutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growth. Semin. Cancer Biol. 2013, 23:149-158.
65. Pillay J., et al. Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences. Cell. Mol. Life Sci. 2013, 70:3813-3827.
66. Fridlender Z.G., Albelda S.M. Tumor-associated neutrophils: friend or foe?. Carcinogenesis 2012, 33:949-955.
67. Dumitru C.A., et al. Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression. Semin. Cancer Biol. 2013, 23:141-148.
68. Brandau S., et al. The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins, siblings or twins?. Semin. Cancer Biol. 2013, 23:171-182.
69. Nozawa H., et al. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:12493-12498.
70. Fridlender Z.G., et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: 'N1' versus 'N2' TAN. Cancer Cell 2009, 16:183-194.
71. Gregory A.D., Houghton A.M. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 2011, 71:2411-2416.
72. Jablonska J., et al. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J. Clin. Invest. 2010, 120:1151-1164.
73. Nowarski R., et al. Innate immune cells in inflammation and cancer. Cancer Immunol. Res. 2013, 1:77-84.
74. Walker J.A., et al. Innate lymphoid cells - how did we miss them?. Nat. Rev. Immunol. 2013, 13:75-87.
75. Castriconi R., et al. Neuroblastoma-derived TGF-beta1 modulates the chemokine receptor repertoire of human resting NK cells. J. Immunol. 2013, 190:5321-5328.
76. Biroccio A., et al. TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells. Nat. Cell Biol. 2013, 15:818-828.
77. Pietra G., et al. Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int. Immunol. 2009, 21:793-801.
78. Tallerico R., et al. Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J. Immunol. 2013, 190:2381-2390.
79. Liu R.B., et al. Densely granulated murine NK cells eradicate large solid tumors. Cancer Res. 2012, 72:1964-1974.
80. Anguille S., et al. Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS ONE 2012, 7:e51851.
81. Mlecnik B., et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci. Transl. Med. 2014, 6:228ra237.
82. Huber S., et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012, 491:259-263.
83. Sonnenberg G.F., et al. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol. 2011, 12:383-390.
84. Kirchberger S., et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J. Exp. Med. 2013, 210:917-931.
85. Diamond M.S., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 2011, 208:1989-2003.
86. Fuertes M.B., et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J. Exp. Med. 2011, 208:2005-2016.
87. Sisirak V., et al. Impaired IFN-alpha production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res. 2012, 72:5188-5197.
88. Watkins S.K., et al. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J. Clin. Invest. 2011, 121:1361-1372.
89. Sceneay J., et al. Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res. 2012, 72:3906-3911.
90. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
91. Ueda Y., et al. Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. J. Exp. Med. 2005, 201:1771-1780.
92. Hestdal K., et al. Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J. Immunol. 1991, 147:22-28.
93. Katoh H., et al. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 2013, 24:631-644.
94. Youn J.I., et al. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 2008, 181:5791-5802.
95. Serafini P., et al. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 2006, 16:53-65.
96. Diaz-Montero C.M., et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 2009, 58:49-59.
97. Youn J.I., et al. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J. Leukoc. Biol. 2012, 91:167-181.
98. Fridlender Z.G., et al. Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS ONE 2012, 7:e31524.
99. Kolaczkowska E., Kubes P. Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 2013, 13:159-175.
100. Christoffersson G., et al. VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. Blood 2012, 120:4653-4662.